News
Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback